Macrophage Activation Syndrome Treated with Anakinra

To the Editor:

A 32-year-old woman originally from Cambodia (living in Canada since 1993) developed symmetrical polyarthritis involving hands, wrists, and knees. Rheumatoid factor (RF) and anticyclic citrullinated peptide (CCP), antinuclear antibody (ANA), and anti-double-stranded DNA (dsDNA) were negative. A diagnosis of seronegative polyarthritis was made. Treatment was initiated with methotrexate, hydroxychloroquine, and sulfasalazine.

Three years later she developed tuberculosis of the spine (Pott’s disease). She underwent surgical debridement and internal fixation of lumbar spine (T12-L1). Antituberculous drugs were initiated. She developed hepatitis secondary to isoniazid and was treated with ethambutol, pyrazinamide, and rifampin for a year, followed by pyrazinamide and rifampin maintenance therapy indefinitely.

Four years after the diagnosis of seronegative arthritis, she was readmitted to our hospital with fever (39°C) and a flare of arthritis. She also presented a sterile pharyngitis, polyadenopathy, and small bilateral pleural effusions. No rash was noted during febrile episodes but she is naturally tanned. Laboratory results showed inflammatory anemia, neutrophilia, and elevated ferritin, sedimentation rate, and C-reactive protein (Table 1). Repeat RF, anti-CCP, and anti-dsDNA examinations were negative and ANA were weakly positive (1/320). Articular radiographs showed distal interphalangeal joint erosions and midcarpal erosions. Bone marrow biopsy was normal. A diagnosis of adult-onset Still’s disease (AOSD) was made. Prednisone doses of 20 mg BID were necessary to abate temperature (Table 1). To the Editor:

Table 1. Maximal daily temperature, laboratory values, and treatments.

<table>
<thead>
<tr>
<th></th>
<th>8 Months Prior to Admission: Spinal Surgery</th>
<th>4 Months Prior to Admission: Diagnosis of AOSD</th>
<th>Admission for MAS</th>
<th>3 Months After Admission</th>
<th>10 Months After Admission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximal temperature (°C)</td>
<td>≤ 37.5</td>
<td>38.5</td>
<td>38.2</td>
<td>37.8</td>
<td>≤ 37.5</td>
</tr>
<tr>
<td>WBC (×10^9 cells/l)</td>
<td>4.0–11.0</td>
<td>5.7</td>
<td>4.2</td>
<td>6.5</td>
<td>4.8</td>
</tr>
<tr>
<td>Hb (g/l)</td>
<td>100</td>
<td>80</td>
<td>87</td>
<td>101</td>
<td>105</td>
</tr>
<tr>
<td>Platelets (×10^9 cells/l)</td>
<td>150–400</td>
<td>233</td>
<td>137</td>
<td>262</td>
<td>281</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>&lt; 20</td>
<td>35</td>
<td>13</td>
<td>13</td>
<td>18</td>
</tr>
<tr>
<td>C-reactive protein (mg/l)</td>
<td>&lt; 8</td>
<td>27</td>
<td>8</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Ferritin (µg/l)</td>
<td>10–150</td>
<td>866</td>
<td>7194</td>
<td>1552</td>
<td>1552</td>
</tr>
<tr>
<td>Treatment</td>
<td>Start antituberculous medication</td>
<td>Start gold salts</td>
<td>Start methylprednisolone</td>
<td>Start anakinra</td>
<td></td>
</tr>
</tbody>
</table>

AOSD: adult-onset Still’s disease; MAS: macrophage activation syndrome; WBC: white blood cells; Hb: hemoglobin; ESR: erythrocyte sedimentation rate.

A dramatic response was observed. Within 48 hours of anakinra treatment, blood count increased and fever abated.

Two months after the diagnosis of MAS, the patient was feeling well with anakinra 100 mg daily and prednisone 5 mg twice daily. She had no more fever and only mild residual joint pain and no synovitis. Ten months after the initiation of anakinra, she is well and has minimal morning stiffness but no other symptoms. Her spinal disease is stable. She also remains on rifampin and pyrazinamide, as well as methotrexate 20 mg subcutaneously once a week, folic acid, hydroxychloroquine 200 mg daily, and prednisone 2 mg per day on a slowly tapering regimen.

This case represents an atypical presentation of AOSD, with seronegative arthritis presenting 4 years before fever. At diagnosis, fever is present in 85%–100% of cases, and arthritis in 64%–100%. The rate of joint disease presenting without fever and evolving to AOSD is unknown. AOSD should be kept in mind in the differential diagnosis of seronegative arthritides.

MAS is a much feared complication of AOSD. This syndrome is part of the histiocytic disorders, and represents an exaggerated activation of the reticuloendothelial system, in which histiocytes (tissue macrophages) phagocytize hematopoietic cells. Mortality rate is 8%–22%. Various triggers have been reported, among them the use of antituberculous agents and gold salts. These might have been triggers in our patient, but the use of antituberculous drugs was longstanding, and gold salts were stopped before the initiation of the syndrome. The prednisone taper with secondary increase of systemic inflammation might also have been responsible. The diagnosis of MAS is sometimes difficult. Diagnostic criteria have been described in children with systemic juvenile idiopathic arthritis. Our case fulfilled these criteria, but there are no diagnostic criteria for adults. It is probable that AOSD and MAS represent a continuum of disease with varying degrees of severity, and that MAS is underdiagnosed in AOSD.

AOSD: adult-onset Still’s disease; MAS: macrophage activation syndrome; WBC: white blood cells; Hb: hemoglobin; ESR: erythrocyte sedimentation rate.
The use of anakinra to treat refractory AOSD is well established. Yet only 1 case report states the efficacy of anakinra as a treatment of MAS, in a 13-year-old patient with systemic-onset juvenile idiopathic arthritis. To our knowledge, this is the first adult case of effective treatment of MAS with anakinra.

This is the first case report of the use of anakinra in a patient with instrumented vertebral fusion for tuberculosis. At 10 months of follow up, there has been no recurrence of tuberculosis. We conclude that macrophage activation syndrome in the setting of AOSD can be treated with anakinra.

MADELEINE DURAND, MD, Department of Internal Medicine; YVES TROYANOV, MD, Department of Rheumatology; PIERRE LAFLAMME, MD, GENEVIEVE GREGOIRE, MD, Department of Microbiology, Hôpital du Sacré-Cœur, 5400 Blvd Gouin West, Montreal, Quebec H4J 1C5, Canada.

Address correspondence to Dr. Durand; E-mail: madeleine.durand@gmail.com

REFERENCES


J Rheumatol 2010;37:4; doi:10.3899/jrheum.091046

Figure 1. Bone marrow aspirate. Broken lines show cytoplasm of histiocytes. White stars show nuclei of histiocytes. Arrows show intracytoplasmic phagocytized nuclei of hematopoietic precursors. White arrowhead shows ghost of phagocytized hematopoietic precursor.